Sukriti Krishan

Sydney, NSW 2052, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies.

PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies.

Journal: Cells

Published: July 15, 2025

Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma.

Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma.

Journal: Cancer medicine

Published: May 21, 2024

Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface.

Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface.

Journal: Cancers

Published: February 08, 2023

The anti-tumor agent, Dp44mT, promotes nuclear translocation of TFEB via inhibition of the AMPK-mTORC1 axis.

The anti-tumor agent, Dp44mT, promotes nuclear translocation of TFEB via inhibition of the AMPK-mTORC1 axis.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: July 15, 2020

Regulation of autophagy and apoptosis by Dp44mT-mediated activation of AMPK in pancreatic cancer cells.

Regulation of autophagy and apoptosis by Dp44mT-mediated activation of AMPK in pancreatic cancer cells.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: October 18, 2019

The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells.

The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells.

Journal: Biochimica et biophysica acta

Published: June 01, 2016

Targeting autophagy in antitumor agent design: furthering the 'lysosomal love' strategy.

Targeting autophagy in antitumor agent design: furthering the 'lysosomal love' strategy.

Journal: Future medicinal chemistry

Published: May 06, 2016

The use of iron chelators in biocidal compositions: evaluation of patent, WO2014059417A1.

The use of iron chelators in biocidal compositions: evaluation of patent, WO2014059417A1.

Journal: Expert opinion on therapeutic patents

Published: December 04, 2014

Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation.

Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation.

Journal: Molecular pharmacology

Published: November 26, 2014

IRON METABOLISM AND AUTOPHAGY: A POORLY EXPLORED RELATIONSHIP THAT HAS IMPORTANT CONSEQUENCES FOR HEALTH AND DISEASE.

IRON METABOLISM AND AUTOPHAGY: A POORLY EXPLORED RELATIONSHIP THAT HAS IMPORTANT CONSEQUENCES FOR HEALTH AND DISEASE.

Journal: Nagoya journal of medical science

Published: September 10, 2014

NDRG1 as a molecular target to inhibit the epithelial-mesenchymal transition: the case for developing inhibitors of metastasis.

NDRG1 as a molecular target to inhibit the epithelial-mesenchymal transition: the case for developing inhibitors of metastasis.

Journal: Future medicinal chemistry

Published: August 28, 2014

Gene of the month. AMP kinase (PRKAA1).

Gene of the month. AMP kinase (PRKAA1).

Journal: Journal of clinical pathology

Published: June 05, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026